Urokinase biosimilar (Suzhou Landing Biological Pharmaceutical)

尿激酶生物类似药 (Suzhou Landing Biological Pharmaceutical)

Report date: 2026/03/20 20:03:07

Base Information

Drug NameUrokinase biosimilar (Suzhou Landing Biological Pharmaceutical)

Drug Alias NameRecombinant human prourokinase (Suzhou Landing Biological Pharmaceutical)重组人尿激酶原（苏州兰鼎生物制药）

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Biosimilar

Mechanisms of ActionPlasminogen activators

TargetsPlasminogen

Therapy Area/IndicationsST Elevation Myocardial Infarction

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesSuzhou RxD Biopharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSuzhou RxD Biopharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsST Elevation Myocardial Infarction

Inactive IndicationsN/A

Other Information

ATC CodeN/A